StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

Axsome Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $187.86M, down 3.5% year over year. For fiscal 2025 it was $183.28M, down 2.0% from the year before. Over ten years it grew 39.1% a year on average. The highest annual figure on record is $187.08M in fiscal 2024.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$183.28M-2.0%
FY2024Dec 31, 2024$187.08M+91.0%
FY2023Dec 31, 2023$97.94M+69.0%
FY2022Dec 31, 2022$57.95M-0.2%
FY2021Dec 31, 2021$58.06M-17.3%
FY2020Dec 31, 2020$70.24M+30.9%
FY2019Dec 31, 2019$53.65M+128.3%
FY2018Dec 31, 2018$23.50M+17.7%
FY2017Dec 31, 2017$19.96M-5.9%
FY2016Dec 31, 2016$21.20M+212.8%
FY2015Dec 31, 2015$6.78M+58.4%
FY2014Dec 31, 2014$4.28M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$46.23M-6.7%
Q1 FY2026Mar 31, 2026$52.68M+17.6%
Q4 FY2025Dec 31, 2025$48.79M-11.3%
Q3 FY2025Sep 30, 2025$40.16M-11.5%
Q2 FY2025Jun 30, 2025$49.54M-0.6%
Q1 FY2025Mar 31, 2025$44.79M+21.6%
Q4 FY2024Dec 31, 2024$55.01M+78.6%
Q3 FY2024Sep 30, 2024$45.39M+57.8%
Q2 FY2024Jun 30, 2024$49.85M+142.2%
Q1 FY2024Mar 31, 2024$36.83M+107.0%
Q4 FY2023Dec 31, 2023$30.80M+109.6%
Q3 FY2023Sep 30, 2023$28.77M+93.4%
Q2 FY2023Jun 30, 2023$20.58M+30.3%
Q1 FY2023Mar 31, 2023$17.79M+41.4%
Q4 FY2022Dec 31, 2022$14.69M+6.6%
Q3 FY2022Sep 30, 2022$14.88M+12.9%
Q2 FY2022Jun 30, 2022$15.79M+8.9%
Q1 FY2022Mar 31, 2022$12.59M-24.2%
Q4 FY2021Dec 31, 2021$13.78M-20.7%
Q3 FY2021Sep 30, 2021$13.18M-10.9%
Q2 FY2021Jun 30, 2021$14.50M+37.6%
Q1 FY2021Mar 31, 2021$16.60M-39.7%
Q4 FY2020Dec 31, 2020$17.38M-9.5%
Q3 FY2020Sep 30, 2020$14.80M-6.6%
Q2 FY2020Jun 30, 2020$10.54M-4.2%
Q1 FY2020Mar 31, 2020$27.52M+262.0%
Q4 FY2019Dec 31, 2019$19.21M+168.6%
Q3 FY2019Sep 30, 2019$15.84M+162.1%
Q2 FY2019Jun 30, 2019$11.00M+98.2%
Q1 FY2019Mar 31, 2019$7.60M+60.0%
Q4 FY2018Dec 31, 2018$7.15M+59.1%
Q3 FY2018Sep 30, 2018$6.04M+35.1%
Q2 FY2018Jun 30, 2018$5.55M+10.8%
Q1 FY2018Mar 31, 2018$4.75M-20.6%
Q4 FY2017Dec 31, 2017$4.49M-22.6%
Q3 FY2017Sep 30, 2017$4.47M-19.7%
Q2 FY2017Jun 30, 2017$5.01M–
Q1 FY2017Mar 31, 2017$5.99M–
Q4 FY2016Dec 31, 2016$5.81M–
Q3 FY2016Sep 30, 2016$5.57M–

More Axsome Therapeutics figures

See a number that looks wrong?